Prevalence and correlates of cardiovascular medication use among nursing home residents with ischemic heart disease: Results from the SHELTER study

Journal of the American Medical Directors Association

Volumn 15, Issue 6, 2014, Pages 410-415

  Foebel, Andrea D ^a,b   Liperoti, Rosa ^a   Gambassi, Giovanni ^a   Gindin, Jacob ^c   Ben Israel, Joshua ^c   Bernabei, Roberto ^a   Onder, Graziano ^a  

^a CATHOLIC UNIVERSITY   (Italy)

^b UNIVERSITY OF WATERLOO   (Canada)

^c UNIVERSITY OF HAIFA   (Israel)

Author keywords

InterRAI; Ischemic heart disease; Nursing home populations; Pharmacotherapy

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ANTITHROMBOCYTIC AGENT;

ADULT; ARTICLE; COGNITIVE DEFECT; COMORBIDITY; DEPRESSION; DISABILITY; DRUG USE; FEMALE; FRANCE; HEALTH CARE FACILITY; HUMAN; ISCHEMIC HEART DISEASE; ITALY; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; NURSING HOME PATIENT; POLYPHARMACY; PREVALENCE; QUESTIONNAIRE; RETROSPECTIVE STUDY; STATISTICAL MODEL; AGED; CLINICAL TRIAL; COGNITION DISORDERS; COHORT ANALYSIS; DIABETES MELLITUS; DISABLED PERSON; DRUG UTILIZATION; DYSPNEA; EUROPE; HEART FAILURE; MULTICENTER STUDY; MYOCARDIAL ISCHEMIA; NURSING HOME; STATISTICS AND NUMERICAL DATA; STROKE; VERY ELDERLY;

ADRENERGIC BETA-ANTAGONISTS; AGED; AGED, 80 AND OVER; ANGIOTENSIN RECEPTOR ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; COGNITION DISORDERS; COHORT STUDIES; COMORBIDITY; DIABETES MELLITUS; DISABLED PERSONS; DRUG UTILIZATION; DYSPNEA; EUROPE; FEMALE; HEART FAILURE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MYOCARDIAL ISCHEMIA; NURSING HOMES; PLATELET AGGREGATION INHIBITORS; POLYPHARMACY; PREVALENCE; RETROSPECTIVE STUDIES; STROKE;

EID: 84901499854     PISSN: 15258610     EISSN: 15389375     Source Type: Journal    
DOI: 10.1016/j.jamda.2013.12.085     Document Type: Article

References (27)

1. Nguyen J.K., Fouts M.M., Kotabe S.E., Lo E. Polypharmacy as a risk factor for adverse drug reactions in nursing home residents. Am J Geriatr Pharmacother 2006, 4:36-41.
2. Catlin A., Cowan C., Hartman M., Heffler S. National Health Expenditure Accounts Team. National health spending in 2006: A year of change for prescription drugs. Health Aff (Millwood) 2008, 27:14-29.
3. Qato D.M., Alexander G.C., Conti R.M., et al. Use of prescription and over-the-counter medications and dietary supplements among older adults in the United States. JAMA 2008, 300:2867-2878.
4. Onder G., Liperoti R., Foebel A., et al. Polypharmacy and mortality among nursing home residents with advanced cognitive impairment: Results from the SHELTER study. JAm Med Dir Assoc 2013, 14:450.e7-450.e12. SHELTER project.
5. McMurdo M.E.T., Witham M.D., Gillespie N.D. Including older people in clinical trials. BMJ 2005, 331:1036-1037.
6. Herrera A.P., Snipes S.A., King D.W., et al. Disparate inclusion of older adults in clinical trials: Priorities and opportunities. Am J Public Health 2010, 100:S105-S112.
7. Crome P., Lally F., Cherubini A., et al. Exclusion of older people from clinical trials: Professional views from nine European countries participating in the PREDICT study. Drugs Aging 2011, 28:667-677.
8. Cherubini A., Oristrell J., Pla X., et al. The persistent exclusion of older patients from ongoing clinical trials regarding heart failure. Arch Intern Med 2011, 171:550-556.
9. Onder G., Liperoti R., Fialova D., et al. Polypharmacy in nursing home in Europe: Results from the SHELTER study. JGerontol A Biol Sci Med Sci 2012, 67:698-704. SHELTER Project.
10. Fihn S.D., Gardin J.M., Abrams J., et al. American College of Cardiology Foundation. 2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS guideline for the diagnosis and management of patients with stable ischemic heart disease: Executive summary: A report of the American College of Cardiology Foundation/American Heart Association task force on practice guidelines, and the American College of Physicians, American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. Circulation 2012, 126:3097-3137.
11. Yusuf S., Islam S., Chow C.K., et al. Prospective Urban Rural Epidemiology (PURE) Study Investigators. Use of secondary prevention drugs for cardiovascular disease in the community in high-income, middle-income, and low-income countries (the PURE Study): A prospective epidemiological survey. Lancet 2011, 378:1231-1243.
12. Tjia J., Briesacher B., Xie D., et al. Disparities in combination drug therapy use in older adults with coronary heart disease. Drugs Aging 2010, 27:149-158.
13. Onder G., Carpenter I., Finne-Soveri H., et al. Assessment of nursing home residents in Europe: The Services and Health for Elderly in Long TERm care (SHELTER) study. BMC Health Serv Res 2012, 12:5. SHELTER Project.
14. Bernabei R., Landi F., Onder G., et al. Second and third generation assessment instruments: The birth of standardization in geriatric care. JGerontol A Biol Sci Med Sci 2008, 63:308-313.
15. Mor V. Acomprehensive clinical assessment tool to inform policy and practice: Applications of the minimum data set. Med Care 2004, 42:III50-III59.
16. Morris J.N., Fries B.E., Morris S.A. Scaling ADLs within the MDS. JGerontol A Biol Sci Med Sci 1999, 54:M546-M553.
17. Morris J.N., Fries B.E., Mehr D.R., et al. MDS Cognitive Performance Scale. JGerontol 1994, 49:M174-M182.
18. Burrows A., Morris J.N., Simon S., et al. Development of a Minimum Data Set-Based Depression Rating Scale for use in nursing homes. Age Ageing 2000, 29:165-172.
19. Hirdes J.P., Frijters D.H., Teare G.F. The MDS-CHESS scale: A new measure to predict mortality in institutionalized older people. JAm Geriatr Soc 2003, 51:96-100.
20. Morris J.N., Carpenter I., Berg K., Jones R.N. Outcome measures for use with home care clients. Can J Aging 2000, 19:87-105.
21. Onder G., Petrovic M., Tangiisuran B., et al. Development and validation of a score to assess risk of adverse drug reactions among hospital patients 65 years or older: The GerontoNet ADR risk score. Arch Intern Med 2010, 170:1142-1148.
22. Foebel A.D., Heckman G.A., Hirdes J.P., et al. Clinical, demographic and functional characteristics associated with pharmacotherapy for heart failure in older home care clients: A retrospective, population-level, cross-sectional study. Drugs Aging 2011, 28:561-573.
23. Angiotensin-converting enzyme inhibition in stable coronary artery disease. NEngl J Med 2004, 351:2058-2068. The PEACE Trial Investigators.
24. Bangalore S., Steg G., Deedwania P., et al. B-Blocker use and clinical outcomes in stable outpatients with and without coronary artery disease. JAMA 2012, 308:1340-1349.
25. Fried T.R., Tinetti M.E., Iannone L. Primary care clinicians' experiences with treatment decision making for older persons with multiple conditions. Arch Intern Med 2011, 171:75-80.
26. Cho S., Lau S.W., Tandon V., et al. Geriatric drug evaluation: Where are we now and where should we be in the future?. Arch Intern Med 2011, 171:937-940.
27. Bernabei R., Caputi A., Di Cioccio L., et al. Need for redesigning pharmacologic research in older individuals. A position statement of the Geriatric Working Group of the Agenzia Italiana del Farmaco (AIFA). JGerontol A Biol Sci Med Sci 2011, 66:66-67.